{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Subacute+Cutaneous+Lupus+Erythematosus", "query": { "condition": "Subacute Cutaneous Lupus Erythematosus" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 17, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Subacute+Cutaneous+Lupus+Erythematosus&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-10T22:46:51.888Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06980805", "title": "A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Subacute Cutaneous Lupus Erythematosus", "Chronic Cutaneous Lupus Erythematosus" ], "interventions": [ { "name": "IMVT-1402", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immunovant Sciences GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2025-02-19", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-06-10T22:46:51.888Z", "location_count": 33, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 28 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06980805" }, { "nct_id": "NCT05162586", "title": "The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Enpatoran low dose", "type": "DRUG" }, { "name": "Enpatoran medium dose", "type": "DRUG" }, { "name": "Enpatoran high dose", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 456, "start_date": "2022-03-31", "completion_date": "2024-11-20", "has_results": true, "last_update_posted_date": "2025-12-01", "last_synced_at": "2026-06-10T22:46:51.888Z", "location_count": 14, "location_summary": "Torrance, California • Brandon, Florida • Miami, Florida + 10 more", "locations": [ { "city": "Torrance", "state": "California" }, { "city": "Brandon", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami Lakes", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05162586" }, { "nct_id": "NCT07332481", "title": "A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Systemic Lupus Erythematosus (SLE)", "Cutaneous Lupus Erythematosus (CLE)" ], "interventions": [ { "name": "Enpatoran", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Standard of care (SoC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 202, "start_date": "2026-03-10", "completion_date": "2029-05-24", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-06-10T22:46:51.888Z", "location_count": 5, "location_summary": "Los Angeles, California • Atlanta, Georgia • Troy, Michigan + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Troy", "state": "Michigan" }, { "city": "Allen", "state": "Texas" }, { "city": "Allen", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07332481" }, { "nct_id": "NCT01389895", "title": "Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous Lupus", "Lupus" ], "interventions": [ { "name": "AMG 557", "type": "DRUG" }, { "name": "AMG 557 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 1, "start_date": "2011-10", "completion_date": "2013-03", "has_results": false, "last_update_posted_date": "2014-01-10", "last_synced_at": "2026-06-10T22:46:51.888Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Austin", "state": "Texas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01389895" }, { "nct_id": "NCT06015737", "title": "A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cutaneous Lupus Erythematosus" ], "interventions": [ { "name": "Anifrolumab", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "COMBINATION_PRODUCT", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 306, "start_date": "2024-06-29", "completion_date": "2027-08-11", "has_results": false, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-06-10T22:46:51.888Z", "location_count": 34, "location_summary": "Phoenix, Arizona • Covina, California • La Jolla, California + 28 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Covina", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06015737" }, { "nct_id": "NCT06875960", "title": "A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Systemic Lupus Erythematosus (SLE)", "Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)" ], "interventions": [ { "name": "BMS-986165", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 35, "start_date": "2026-02-24", "completion_date": "2026-12-01", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-06-10T22:46:51.888Z", "location_count": 4, "location_summary": "Farmington, Connecticut • New York, New York • Oklahoma City, Oklahoma + 1 more", "locations": [ { "city": "Farmington", "state": "Connecticut" }, { "city": "New York", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Jackson", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06875960" }, { "nct_id": "NCT05531565", "title": "A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Subacute Cutaneous Lupus Erythematosus", "Chronic Cutaneous Lupus Erythematosus" ], "interventions": [ { "name": "Litifilimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 450, "start_date": "2022-09-13", "completion_date": "2027-12-14", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-06-10T22:46:51.888Z", "location_count": 61, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 51 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05531565" }, { "nct_id": "NCT06044337", "title": "A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Subacute Cutaneous Lupus Erythematosus", "Chronic Cutaneous Lupus Erythematosus" ], "interventions": [ { "name": "BIIB059 (litifilimab)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 322, "start_date": "2023-10-03", "completion_date": "2029-12-11", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-06-10T22:46:51.888Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06044337" }, { "nct_id": "NCT06013995", "title": "A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lupus" ], "interventions": [ { "name": "BMS-986326", "type": "DRUG" }, { "name": "Placebo for BMS-986326", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 45, "start_date": "2023-09-21", "completion_date": "2026-04-14", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-06-10T22:46:51.888Z", "location_count": 7, "location_summary": "San Diego, California • Clearwater, Florida • Tampa, Florida + 4 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT06013995" }, { "nct_id": "NCT01923415", "title": "A Non-drug Study Profiling Cutaneous Lupus", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lupus Erythematosus, Cutaneous", "Lupus Erythematosus, Systemic", "Lupus Erythematosus, Discoid" ], "interventions": [ { "name": "No intervention, skin biopsy", "type": "PROCEDURE" }, { "name": "No intervention, blood collection", "type": "PROCEDURE" }, { "name": "No intervention, urine collection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 29, "start_date": "2013-04", "completion_date": "2014-08", "has_results": false, "last_update_posted_date": "2014-09-12", "last_synced_at": "2026-06-10T22:46:51.888Z", "location_count": 2, "location_summary": "Indianapolis, Indiana • Dallas, Texas", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01923415" } ] }